News & Events

Professionals in a conference room analyze data on a screen for outcomes research study 'Evaluating the Tolerability of Immune Globulin Intravenous 10% (BIVIGAM®).
Real-world retrospective cohort study evaluating the tolerability of immune globulin intravenous 10% (BIVIGAM®)

Real-world retrospective cohort study evaluating the tolerability of immune globulin intravenous 10% (BIVIGAM®)

Abstract Introduction Intravenous immune globulin 10% liquid (IVIG 10%) is used in the treatment of primary immunodeficiency (PID). Originally approved in 2012 and then voluntarily withdrawn in 2016, IVIG 10% (BIVIGAM®) underwent manufacturing process improvements...

Read More

CHEST Annual Meeting 2025

CHEST Annual Meeting 2025

Chicago, IL #CHEST2025 kicks off on October 19 in Chicago, and we are thrilled to be an exhibitor alongside our colleagues supporting "education for the next era of Chest medicine." If you'll be attending, stop by the Healix booth #740 to learn about how our...

Read More